Literature DB >> 19225411

Neuroanatomic profile of polyglutamine immunoreactivity in Huntington disease brains.

Emily S Herndon1, Christa L Hladik, Ping Shang, Dennis K Burns, Jack Raisanen, Charles L White.   

Abstract

A pathologic hallmark of Huntington disease (HD) is the presence of intraneuronal aggregates of polyglutamine-containing huntingtin protein fragments. Monoclonal antibody 1C2 is a commercial antibody to normal human TATA-binding protein that detects long stretches of glutamine residues. Using 1C2 as a surrogate marker formutant huntingtin protein, we immunostained 19 HD cases, 10 normal controls, and 10 cases of frontotemporal degeneration with ubiquitinated inclusions as diseased controls. In the HD cases, there was consistent 1C2 immunoreactivity in the neocortex, striatum, hippocampus, lateral geniculate body, basis pontis, medullary reticular formation, and cerebellar dentate nucleus. The normal and diseased controls demonstrated 1C2 immunoreactivity only in the substantia nigra, locus coeruleus, and pituitary gland. Staining of 5 HD cases and 5 normal controls revealed a less consistent and less diagnostically useful morphologic immunoreactivity profile. These results indicate that widespread 1C2 immunoreactivity is present in diverse central nervous system areas in HD, and that in the appropriate setting, 1C2 staining can be a useful tool in the postmortem diagnosis of HD when neuromelanin-containing neuronal populations are avoided.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19225411      PMCID: PMC2756075          DOI: 10.1097/NEN.0b013e318198d320

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  25 in total

1.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

2.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

3.  Strong aggregation and increased toxicity of polyleucine over polyglutamine stretches in mammalian cells.

Authors:  Josephine C Dorsman; Barry Pepers; Dennis Langenberg; Henri Kerkdijk; Marije Ijszenga; Johan T den Dunnen; R A C Roos; Gert-Jan B van Ommen
Journal:  Hum Mol Genet       Date:  2002-06-15       Impact factor: 6.150

4.  Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins.

Authors:  K L Double; L Zecca; P Costi; M Mauer; C Griesinger; S Ito; D Ben-Shachar; G Bringmann; R G Fariello; P Riederer; M Gerlach
Journal:  J Neurochem       Date:  2000-12       Impact factor: 5.372

5.  Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias.

Authors:  Y Trottier; Y Lutz; G Stevanin; G Imbert; D Devys; G Cancel; F Saudou; C Weber; G David; L Tora
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

6.  Insoluble TATA-binding protein accumulation in Huntington's disease cortex.

Authors:  Willeke M C van Roon-Mom; Suzanne J Reid; A Lesley Jones; Marcy E MacDonald; Richard L M Faull; Russell G Snell
Journal:  Brain Res Mol Brain Res       Date:  2002-12-30

7.  An aggregate-prone conformational epitope in trinucleotide repeat diseases.

Authors:  Keizo Sugaya; Shiro Matsubara; Kazuhito Miyamoto; Akihiro Kawata; Hideaki Hayashi
Journal:  Neuroreport       Date:  2003-12-19       Impact factor: 1.837

8.  Neuropathological classification of Huntington's disease.

Authors:  J P Vonsattel; R H Myers; T J Stevens; R J Ferrante; E D Bird; E P Richardson
Journal:  J Neuropathol Exp Neurol       Date:  1985-11       Impact factor: 3.685

9.  A comparison of huntington disease and huntington disease-like 2 neuropathology.

Authors:  Dobrila D Rudnicki; Olga Pletnikova; Jean-Paul G Vonsattel; Christopher A Ross; Russell L Margolis
Journal:  J Neuropathol Exp Neurol       Date:  2008-04       Impact factor: 3.685

10.  Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions.

Authors:  Astrid Lunkes; Katrin S Lindenberg; Léa Ben-Haïem; Chantal Weber; Didier Devys; G Bernhard Landwehrmeyer; Jean-Louis Mandel; Yvon Trottier
Journal:  Mol Cell       Date:  2002-08       Impact factor: 17.970

View more
  23 in total

1.  Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.

Authors:  Andrew T N Tebbenkamp; Cameron Green; Guilian Xu; Eileen M Denovan-Wright; Aaron C Rising; Susan E Fromholt; Hilda H Brown; Debbie Swing; Ronald J Mandel; Lino Tessarollo; David R Borchelt
Journal:  Hum Mol Genet       Date:  2011-04-22       Impact factor: 6.150

2.  Coexistence of Huntington's disease and amyotrophic lateral sclerosis: a clinicopathologic study.

Authors:  Mari Tada; Elizabeth A Coon; Alexander P Osmand; Patricia A Kirby; Wayne Martin; Marguerite Wieler; Atsushi Shiga; Hiroe Shirasaki; Masayoshi Tada; Takao Makifuchi; Mitsunori Yamada; Akiyoshi Kakita; Masatoyo Nishizawa; Hitoshi Takahashi; Henry L Paulson
Journal:  Acta Neuropathol       Date:  2012-06-27       Impact factor: 17.088

Review 3.  Huntington's disease: can mice lead the way to treatment?

Authors:  Zachary R Crook; David Housman
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

4.  Neurotrophin receptor p75(NTR) mediates Huntington's disease-associated synaptic and memory dysfunction.

Authors:  Verónica Brito; Albert Giralt; Lilian Enriquez-Barreto; Mar Puigdellívol; Nuria Suelves; Alfonsa Zamora-Moratalla; Jesús J Ballesteros; Eduardo D Martín; Nuria Dominguez-Iturza; Miguel Morales; Jordi Alberch; Sílvia Ginés
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

5.  αB-Crystallin overexpression in astrocytes modulates the phenotype of the BACHD mouse model of Huntington's disease.

Authors:  Ana Osório Oliveira; Alexander Osmand; Tiago Fleming Outeiro; Paul Joseph Muchowski; Steven Finkbeiner
Journal:  Hum Mol Genet       Date:  2016-02-26       Impact factor: 6.150

6.  Protein misfolding detected early in pathogenesis of transgenic mouse model of Huntington disease using amyloid seeding assay.

Authors:  Sharad Gupta; Shy'Ann Jie; David W Colby
Journal:  J Biol Chem       Date:  2011-12-20       Impact factor: 5.157

Review 7.  New developments in RAN translation: insights from multiple diseases.

Authors:  John Douglas Cleary; Laura Pw Ranum
Journal:  Curr Opin Genet Dev       Date:  2017-03-30       Impact factor: 5.578

8.  Identification of novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease.

Authors:  Mikko Airavaara; Olga Pletnikova; Maire E Doyle; Yong E Zhang; Juan C Troncoso; Qing-Rong Liu
Journal:  J Biol Chem       Date:  2011-11-11       Impact factor: 5.157

9.  A neurotoxic phosphoform of Elk-1 associates with inclusions from multiple neurodegenerative diseases.

Authors:  Anup Sharma; Linda M Callahan; Jai-Yoon Sul; Tae Kyung Kim; Lindy Barrett; Minsun Kim; James M Powers; Howard Federoff; James Eberwine
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

10.  RAN Translation in Huntington Disease.

Authors:  Monica Bañez-Coronel; Fatma Ayhan; Alex D Tarabochia; Tao Zu; Barbara A Perez; Solaleh Khoramian Tusi; Olga Pletnikova; David R Borchelt; Christopher A Ross; Russell L Margolis; Anthony T Yachnis; Juan C Troncoso; Laura P W Ranum
Journal:  Neuron       Date:  2015-11-18       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.